TX-MARY-KAY
8.12.2022 18:16:34 CET | Business Wire | Press release
Today, Mary Kay Inc., a global advocate for corporate sustainability and environmental stewardship, announced the completion of a reforestation project in Madagascar in partnership with the Arbor Day Foundation, Omaha’s Henry Doorly Zoo and Aquarium, and the Madagascar Biodiversity Partnership. The announcement comes as representatives from around the world gather in Montreal at the United Nations Convention on Biological Diversity (COP 15) to tackle the world’s biodiversity crisis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005696/en/
(Credit: Mary Kay Inc.)
Sustainable forest management is essential to biodiversity conservation. The 42,000-tree project in Southeast Madagascar focused on reversing decades of forest destruction. The forest is home to critically endangered lemurs and other wildlife species found nowhere else on earth. Tree planting efforts were also intended to improve resiliency for the forest and neighboring communities.
The Arbor Day Foundation estimates* that over the next 40 years, the project will result in:
- 10,562 metric tons of net carbon dioxide sequestered (the equivalent to 2,296 fewer cars on the road)
- 125 tons of air pollution removed (the equivalent to enough oxygen for 10,500 people)
- 2,627,176 gallons avoided of water runoff (the equivalent to 29,854 people with cleaner water)
“The impact of this partnership has allowed us to make significant strides in one of the most critical forestlands for biodiversity, with many species depending on these trees for survival,” said Katie Loos, Chief Operating Officer of the Arbor Day Foundation. “Mary Kay has continued to demonstrate their dedicated support towards strengthening our planet’s forests of greatest need. Protecting and preserving our most vulnerable species is essential to solving the current biodiversity crisis, and we are proud to work with partners who share this value.”
Just last month, Mary Kay announced the completion of a 69-acre reforestation project to revitalize Florida’s Econfina Creek Wildlife Management Area in partnership with the Arbor Day Foundation. Working alongside the Northwest Florida Water Management District, the Foundation and Mary Kay partnered to plant 43,000 longleaf pine that will help protect critical water resources in Bay County Florida. Key project environmental and biodiversity benefits included: restoring and preserving the primary source of drinking water for Bay County, Florida; replanting native tree species to return this area to its natural state; and improving the habitat for area wildlife including deer, bobwhite quail, Sherman’s fox squirrels, and gopher tortoises.
Earlier this year, Mary Kay also released a report detailing its long-standing partnership with the Arbor Day Foundation. Together, Mary Kay Inc. and the Foundation have planted over 1.2 million trees across the globe, making a measurable impact on vital forest ecosystems.
To read more about Mary Kay’s commitment to sustainability, visit marykayglobal.com/sustainability and download Mary Kay’s global sustainability strategy: Enriching Lives Today for a Sustainable Tomorrow.
*Impact estimates made using i-Tree, a state-of-the-art, peer-reviewed software suite from the USDA Forest Service that provides urban and rural forestry analysis and benefits assessment tools.
About the Arbor Day Foundation
Founded in 1972, the Arbor Day Foundation has grown to become the largest nonprofit membership organization dedicated to planting trees, with more than one million members, supporters, and valued partners. Over the past 50 years, almost 500 million Arbor Day Foundation trees have been planted in neighborhoods, communities, cities, and forests throughout the world. Our vision is to lead toward a world where trees are used to solve issues critical to survival.
As one of the world’s largest operating conservation foundations, the Arbor Day Foundation, through its members, partners, and programs, educates and engages stakeholders and communities across the globe to involve themselves in its mission of planting, nurturing and celebrating trees. More information is available at arborday.org.
About Mary Kay Inc.
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors of domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221208005696/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
